Mechanism
PCO-371 (also known as PC-0371) is an orally active, non-peptide small molecule that acts as a selective full agonist and "molecular wedge" of the parathyroid hormone receptor type 1 (PTHR1).
Receptor Activation and Signaling: By binding to PTHR1, PCO-371 stimulates downstream second-messenger cascades, notably intracellular cAMP production and associated protein kinase pathways within skeletal tissues.
Impact on Chondrogenesis and Bone Turnover: In the epiphyseal growth plate, parathyroid hormone-related protein (PTHrP) and its receptor signaling play a fundamental role in regulating chondrocyte proliferation and delaying terminal hypertrophy. Intermittent or targeted activation of the PTH1R pathway by a small-molecule agonist like PCO-371 could theoretically mimic aspects of this regulation, supporting chondrocyte pool maintenance and preventing premature epiphyseal fusion.
Cellular Constraints and Barriers: Conversely, excessive or continuous hyperactivation of bone remodeling axes can lead to structural limitations or imbalances. Optimizing the pharmacokinetic window is critical to prevent signaling barrier that could otherwise impair normal plate architecture.
Dosing
Based on early clinical and preclinical evaluations (such as Phase I trials like NCT02475616 evaluating single ascending doses in healthy subjects):
* Oral Bioavailability: Unlike traditional peptide hormone therapies (such as teriparatide), PCO-371 was engineered as an orally active small-molecule agent designed for systemic distribution.
* Target Engagement: Preclinical and early Phase data focus on achieving controlled receptor engagement without the sharp pharmacokinetic peaks typical of injected biologics.
Theoretical Growth Potential
Assuming open growth plates and balanced endocrine factors, utilizing an oral PTHR1 small-molecule agonist like PCO-371 to modulate chondrocyte proliferation and delay senescence could theoretically support an extended growth window. Under ideal theoretical models, this might contribute an estimated 2 to 5 cm of extra longitudinal growth over an extended cycle. However, this remains a purely theoretical
What do you think about it?
Studies
PMID: 30948831
PMID: 37286842
ClinicalTrials.gov
ID: NCT02475616
PCO-371 (also known as PC-0371) is an orally active, non-peptide small molecule that acts as a selective full agonist and "molecular wedge" of the parathyroid hormone receptor type 1 (PTHR1).
Receptor Activation and Signaling: By binding to PTHR1, PCO-371 stimulates downstream second-messenger cascades, notably intracellular cAMP production and associated protein kinase pathways within skeletal tissues.
Impact on Chondrogenesis and Bone Turnover: In the epiphyseal growth plate, parathyroid hormone-related protein (PTHrP) and its receptor signaling play a fundamental role in regulating chondrocyte proliferation and delaying terminal hypertrophy. Intermittent or targeted activation of the PTH1R pathway by a small-molecule agonist like PCO-371 could theoretically mimic aspects of this regulation, supporting chondrocyte pool maintenance and preventing premature epiphyseal fusion.
Cellular Constraints and Barriers: Conversely, excessive or continuous hyperactivation of bone remodeling axes can lead to structural limitations or imbalances. Optimizing the pharmacokinetic window is critical to prevent signaling barrier that could otherwise impair normal plate architecture.
Dosing
Based on early clinical and preclinical evaluations (such as Phase I trials like NCT02475616 evaluating single ascending doses in healthy subjects):
* Oral Bioavailability: Unlike traditional peptide hormone therapies (such as teriparatide), PCO-371 was engineered as an orally active small-molecule agent designed for systemic distribution.
* Target Engagement: Preclinical and early Phase data focus on achieving controlled receptor engagement without the sharp pharmacokinetic peaks typical of injected biologics.
Theoretical Growth Potential
Assuming open growth plates and balanced endocrine factors, utilizing an oral PTHR1 small-molecule agonist like PCO-371 to modulate chondrocyte proliferation and delay senescence could theoretically support an extended growth window. Under ideal theoretical models, this might contribute an estimated 2 to 5 cm of extra longitudinal growth over an extended cycle. However, this remains a purely theoretical
What do you think about it?
Studies
PMID: 30948831
PMID: 37286842
ClinicalTrials.gov
ID: NCT02475616
